Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$128.04 USD

128.04
1,506,076

-0.87 (-0.67%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $127.60 -0.44 (-0.34%) 5:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up

by Zacks Equity Research

Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.

Zacks Equity Research

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

by Zacks Equity Research

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.

Zacks Equity Research

AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.

Zacks Equity Research

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

by Zacks Equity Research

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

John Blank headshot

Will Big Stocks Make Big Headlines? Global Week Ahead

by John Blank

This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.

Vaishali Doshi headshot

Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns

by Vaishali Doshi

Here are four top-performing liquid stocks, Neurocrine Biosciences (NBIX), GigaCloud Technology (GCT), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for robust returns.

Zacks Equity Research

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?

by Zacks Equity Research

Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYG

Zacks Equity Research

Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYG

Zacks Equity Research

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

by Zacks Equity Research

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

Zacks Equity Research

Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

by Zacks Equity Research

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

Zacks Equity Research

Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.